Ava Announces Major New Strategic Partnership and Board Members
An alliance with leading pharmaceutical firm Aristo Pharma and board member appointments signal a new era in the women’s health firm’s growth.
ZURICH – July 15, 2021 – Ava, maker of the first FDA-cleared and CE-marked wearable fertility tracking device, today announced a major strategic partnership in Europe and new appointments to its board.
Ava has forged a strategic alliance with the Berlin-based pharmaceutical company Aristo Pharma GmbH, one of the leading women’s health companies in Germany. Through the partnership, Ava and Aristo will access patients right at the doctor’s office, leveraging Aristo’s European healthcare provider network and adding an innovative offering to Aristo’s women’s health portfolio.
“Reproductive health is something women discuss with their providers. Our partnership with Aristo allows Ava to be part of that conversation,” said Ava CEO Lea von Bidder. “We’re developing a system to strengthen that relationship by helping providers better serve their patients.
“We’ve always been a clinical research and publication-driven organization, and those competencies make us an ideal fit for doctor’s offices,” she said.
Aristo CEO Dr. Stefan Koch said, “Digital applications are becoming increasingly important in the healthcare market. We are very happy that with Ava we have found a partner who enables us to meet exactly this demand, offering physicians and consumers an additional modern option for managing reproductive health. The feedback from physicians so far has been extremely positive.”
The Ava Fertility Tracker detects a woman’s five most fertile days in real-time with 90% accuracy, while also delivering AI-driven insights about her reproductive health. The device has helped women to conceive over 50,000 times, a number set to grow exponentially as Ava’s B2B market expands in Europe with Aristo, and in the US, where Ava is being increasingly adopted by companies as a fertility benefit for their employees.
This expansion comes as Ava announces the appointment of Barbara Staehelin as the new chair of the Board. Staehelin, former Head of Diagnostics Development at Roche, brings significant board and healthcare leadership experience to Ava, including a deep understanding of healthcare markets. “I look forward to advancing women’s health at Ava with my new colleagues. This talented team is poised to positively impact the fertility journeys of women worldwide.”
Additionally, Monika Kruesi and Amir Orad were elected as members of the Board. Kruesi is an experienced board director, with mandates in companies ranging from energy business, technology, to the automotive industry. She has been advising Ava’s board for the past five years. Orad is the CEO of Sisense, a New York-based AI-driven data-analytics platform used by over 2,000 companies worldwide. A serial entrepreneur and thought leader in the financial technology and cyber security domains, he has been named “EY Entrepreneur of the Year for Technology” and one of “Goldman Sachs 100 Most Intriguing Entrepreneurs.”
“I thought it was incredible that one of the company’s KPIs was how many ‘Ava babies’ were born,” Orad said of the appointment. “I felt inspired by the opportunity to see data, analytics and AI used, not for securities or banking, but to help people build their families.”
Ava’s mission is to advance women’s health by applying artificial intelligence and clinical research to previously understudied areas and developing tech-driven products that assist women throughout the stages of their reproductive lifetime.
For more information or to schedule an interview, contact email@example.com.
Ava is a digital health company with offices in Zurich, San Francisco, Belgrade, and Makati that advances women’s reproductive health by bringing together artificial intelligence and clinical research. Its fertility tracking sensor bracelet detects the five most fertile days of a woman’s cycle in real-time with 90% accuracy, while also delivering personalized insight about reproductive health and pregnancy.
Worn only during sleep, the Ava bracelet* tracks multiple physiological parameters including pulse rate, breathing rate, and skin temperature. Launched in the US in 2016, the Ava bracelet is now sold in 36 countries and has helped more than 50,000 women become pregnant. Studies for the clinical use of Ava have been conducted in collaboration with academic partners around the world, including at the University Hospital of Zurich, Switzerland, Columbia University, and Northwestern University’s Feinberg School of Medicine. Ava was voted Best of Baby Tech at CES, named a Women’s Health “Editors’ Choice” product and has been honored as a CB Insights Digital Health 150 company. For more information on Ava, visit www.avawomen.com.
*The Ava Fertility Tracker is the only FDA-cleared fertility tracking wearable and is also CE-marked according to MDR 2017/745 for the purpose of measuring and displaying physiological parameters to facilitate conception and to provide general information on health and wellness to users.